The actions will create a slimmed-down commercial-stage company focused on selling hepatitis B vaccine HEPLISAV-B.

Nektar Therapeutics created Inheris Biopharma, a new subsidiary that will take over the launch of Nektar’s pain drug, NKTR-181.

In this week's EuroBiotech Report, Novartis bests GSK in asthma trial, Affimed scraps T-cell engager program and Amgen inks Nuevolution buyout.

In our EuroBiotech roundup this week, Boehringer backs startup, Zealand delays filing plan and Scancell eyes cancer trial start.

Tonix Pharmaceuticals is licensing a phase 2 treatment for cocaine intoxication from Columbia University.

Affimed has terminated its bispecific T-cell engager program after the FDA hit it with a clinical hold and shifted ts focus to innate cell engagers.

Locana raised $55 million to expand its platform and pipeline for diseases caused by problems in RNA that stop the production of essential proteins.

Scott Gottlieb has slipped right back into his old ways, becoming "special partner" at his old life science VC firm New Enterprise Associates.